Health and Healthcare

Biogen : BIIB

All Biogen Articles

607 Articles

Chris Lange | Oct 23, 2016 at 10:35 AM EDT

Top Health Care Earnings Coming Next Week

Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of…

Lee Jackson | Oct 20, 2016 at 9:55 AM EDT

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.

Chris Lange | Oct 12, 2016 at 7:10 AM EDT

Short Sellers Have Mixed Views on Major Biotechs

If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a…

Chris Lange | Oct 2, 2016 at 10:05 AM EDT

Top 6 Biopharma Gainers of the Past Week

Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood…

Chris Lange | Sep 28, 2016 at 11:15 AM EDT

Anavex Soars on Biogen Agreement

Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.

Chris Lange | Sep 27, 2016 at 7:50 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest moves were upward across…

Chris Lange | Sep 13, 2016 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 31 short interest data have been compared with the previous report, and short interest decreased for most of…

Jon C. Ogg | Sep 6, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Biogen, Broadcom, Devon Energy, Gilead Sciences, Mondelez and…

Chris Lange | Aug 25, 2016 at 8:40 AM EDT

Short Sellers Increase Bets in Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across…

Lee Jackson | Aug 11, 2016 at 8:20 AM EDT

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.

Chris Lange | Aug 10, 2016 at 8:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech…

Lee Jackson | Aug 4, 2016 at 10:40 AM EDT

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that…

Jon C. Ogg | Aug 3, 2016 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66, Rubicon Project and More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Biogen, Discovery Communications, Mosaic, Plains All American, Phillips…

Lee Jackson | Aug 1, 2016 at 9:25 AM EDT

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there…

Chris Lange | Aug 1, 2016 at 9:05 AM EDT

How Biogen and Ionis Won Big (and Can Win More) From Late Stage Trial

Shares of Biogen and, especially, Ionis Pharmaceuticals made handy gains early Monday morning following favorable interim results from a late-stage…

1 … 18 19 20 21 22 … 41

Biogen : BIIB

All Biogen Articles

Top Health Care Earnings Coming Next Week

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Short Sellers Have Mixed Views on Major Biotechs

Top 6 Biopharma Gainers of the Past Week

Anavex Soars on Biogen Agreement

Short Sellers Increase Bets in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More

Short Sellers Increase Bets in Major Biotechs

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Short Sellers Run for Cover From Major Biotechs

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Top Analyst Upgrades and Downgrades: Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66, Rubicon Project and More

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

How Biogen and Ionis Won Big (and Can Win More) From Late Stage Trial

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

Biogen : BIIB

All Biogen Articles

Top Health Care Earnings Coming Next Week

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Short Sellers Have Mixed Views on Major Biotechs

Top 6 Biopharma Gainers of the Past Week

Anavex Soars on Biogen Agreement

Short Sellers Increase Bets in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More

Short Sellers Increase Bets in Major Biotechs

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Short Sellers Run for Cover From Major Biotechs

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Top Analyst Upgrades and Downgrades: Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66, Rubicon Project and More

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

How Biogen and Ionis Won Big (and Can Win More) From Late Stage Trial

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line